Skip to main content
Linda Mileshkin on Muck Rack

Linda Mileshkin

Melbourne
As seen in: Color Research & Application, Nature, Australian Broadcasting Corporation (ABC), JAMA Oncology, The Lancet, International Journal of Radiation Oncology*Biology*Physics, touchONCOLOGY
Medical Oncologist, Gynaecological and Lung Cancers, Carcinoma of Unknown Primary. Views are entirely my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Linda

Contact Linda, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2 : phase 2 EMBRACE trial

|
By Katrin M. Sjoquist, Alexander Dobrovic, Kristy P. Robledo, Ksenija Nesic, Sally Baron-Hay, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Sonia Yip, Linda Mileshkin, J. Lynn Fink, Lisa Bailey, Yvonne Lee, Danka S Zebic, Kristy Shield-Artin, Anthony T. Papenfuss, Olga Kondrashova, Matthew Wakefield, Cassandra J. Vandenberg, Martin R. Stockler, Clare Scott Verified, Paul M. Waring, Sumitra Ananda, Garry Chang, U. G. Imalki U. Kariyawasam, Andrew Jarratt
| Nature Verified
Abstract Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (meBRCA1) or RAD51C (meRAD51C) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD.
Open in Who Shared Issue with article?

Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary - Nature Communications

|
By Richard J. Rebello, Atara Posner, Ruining Dong, Camilla B. Mitchell, Catherine Mitchell, Sehrish Kanwal, Hui-Li Wong, Shiva Balachander, Shannon Nicolson, Anna deFazio, Ian Collins, Christopher Steer, Andrew Fellowes, Rodney Hicks, Charles Shale, Sarah-Jane Dawson, Stephen Fox, Sean Grimmond, Linda Mileshkin
| Nature Verified
Abstract Genomics can inform both tissue-of-origin (TOO) and precision treatments for patients with cancer of unknown primary (CUP). Here, we use whole genome and transcriptome sequencing (WGTS) for 72 patients and show diagnostic superiority of WGTS over panel testing (386–523 genes) in 71 paired cases. WGTS detects all reportable DNA features found by panel as well as additional mutations of diagnostic or therapeutic relevance in 76% of cases.
Open in Who Shared Issue with article?

Unravelling mutational signatures with plasma circulating tumour DNA - Nature Communications

|
By Sebastian Hollizeck, Richard J. Rebello, Sehrish Kanwal, Ruining Dong, Sean Grimmond, Linda Mileshkin, Richard W. Tothill, Dineika Chandrananda
| Nature Verified
Abstract The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational signature detection using low-coverage whole-genome sequencing of ctDNA.
Open in Who Shared Issue with article?
See all 24 articles